Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 42.9%GRADE not reported 2 · 28.6%Very low 2 · 28.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Death Analysis 1.1 · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes all‐cause mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

1 finding from 1 review

Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
RR 0.55 [0.26, 1.19]
1 study · 40 participants
Very low

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

First‐time symptomatic venous thromboembolism · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

1 finding from 1 review

Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
GRADE not reported

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Major bleeding · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

1 finding from 1 review

Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
RR 0.1 [0.01, 1.94]
1 study · 40 participants
Very low

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Quality of life ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Asymptomatic venous thromboembolism · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

1 finding from 1 review

Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Clinically relevant non‐major bleeding ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found